Has healthcare embraced a hit-and-run strategy? Forbes Its justification for Sovaldi's hefty price is rock-solid: $84,000 for a cure is far cheaper than liver transplants that don't prevent relapses, and much better for patients than debilitating interferon-based therapies. It is also more defensible than ... |
